Welcome to our dedicated page for Biofrontera news (Ticker: BFRI), a resource for investors and traders seeking the latest updates and insights on Biofrontera stock.
Biofrontera Inc. (NASDAQ: BFRI) is a U.S.-based biopharmaceutical company specializing in dermatology and photodynamic therapy (PDT). Its news flow centers on the commercialization and clinical development of Ameluz® and the RhodoLED® lamp series for the treatment of actinic keratoses and other skin conditions.
On this page, readers can follow company announcements related to financial results, such as quarterly and annual revenue updates, as well as business updates describing trends in Ameluz® sales and operating expenses. Biofrontera frequently reports on revenue performance, gross margin developments, and the impact of its strategic agreements on its financial profile.
News items also highlight clinical and regulatory milestones. These include database locks and completion of clinical studies in actinic keratosis on peripheral body areas, Phase 1 pharmacokinetics data, Phase 3 results in superficial basal cell carcinoma, and Phase 2 progress in acne vulgaris. The company uses press releases to describe how these data support supplemental New Drug Applications and future Phase 3 programs.
In addition, Biofrontera issues updates on strategic transactions and capital markets activity, such as the acquisition of all U.S. rights to Ameluz® and RhodoLED® from Biofrontera AG, changes to royalty and earnout structures, private placements of convertible preferred stock, and the divestiture of its Xepi® antibiotic cream license. Regulatory notices regarding Nasdaq listing compliance and participation in investor conferences are also part of the company’s regular news flow.
Investors and observers who want to track developments in dermatologic photodynamic therapy, label expansion efforts for Ameluz®-PDT, and Biofrontera’s financial and strategic progress can use this news feed as a centralized source of company-issued updates.
Summary not available.
Biofrontera Inc. (NASDAQ:BFRI) announced the completion of the last patient visit in a Phase I study for Ameluz® - PDT aimed at treating mild to severe actinic keratosis (AK). The study, conducted by Biofrontera Bioscience GmbH, explored the safety and tolerability of using three tubes of BF-200 ALA 10% gel in expanded treatment fields. Top line results are anticipated in Q4 2023. CEO Erica Monaco emphasized this milestone as a significant advancement, potentially allowing broader treatment areas and fewer office visits for patients. Actinic keratosis is a common pre-cancerous condition affecting approximately 58 million U.S. residents, highlighting the importance of effective treatment options.
Biofrontera Inc. (NASDAQ:BFRI) announced a significant investment in expanding its salesforce by almost 30%, thereby increasing coverage to 40 territories in 2023. This strategic move aims to enhance outreach for their FDA-approved therapy for actinic keratosis, Ameluz®-PDT, further penetrating dermatology markets. CEO Erica Monaco highlighted the company’s success in 2022, achieving record revenues and market share with a reduced sales team. The addition of 140 years of healthcare experience is expected to bolster growth and market presence. The company remains optimistic about future performance despite potential challenges outlined in their forward-looking statements.
Biofrontera Inc. (NASDAQ:BFRI) is set to showcase its FDA-approved dermatological products at the 2023 American Academy of Dermatology (AAD) Annual Meeting from March 17-21 in New Orleans, LA. The company will demonstrate the photodynamic therapy (PDT) procedure using the RhodoLED lamp at booth #2224. CEO Erica Monaco stated the event is an opportunity to educate dermatologists about the Ameluz PDT therapy for treating actinic keratoses. The AAD Annual Meeting is the largest dermatologic event, attracting about 18,000 attendees, including around 10,000 medical personnel. Biofrontera aims to enhance its outreach among dermatology professionals during this major conference.
Summary not available.
Biofrontera (NASDAQ:BFRI) reported strong financial results for 2022, with total revenues reaching $28.7 million, a 19% increase from 2021. The fourth quarter revenues grew 11% year-over-year to $10.1 million. Notably, Ameluz revenues exceeded pre-COVID levels, increasing 12% from the 2019 record. The company plans to expand its sales force to 50-55 by 2025, aiming for a 25% revenue growth in 2023. Despite improving metrics, the net loss for 2022 narrowed to $640,000 from $37.7 million in 2021. Adjusted EBITDA remained negative at $18.1 million.
Biofrontera, Inc. (NASDAQ:BFRI), a biopharmaceutical company focused on dermatological treatments, will present at the 35th Annual ROTH Conference in Laguna Nigel, CA, from March 12-14, 2023. CEO Erica Monaco and CFO Fred Leffler will represent the company. Their presentation is scheduled for March 13, 2023, at 8:00 AM PT, and can be viewed live here. An archive will be available after the event. Biofrontera specializes in photodynamic therapy and topical antibiotics for skin conditions, including actinic keratoses and impetigo. For more details, visit www.biofrontera-us.com.
Biofrontera Inc. (NASDAQ:BFRI) has announced that it will release its fourth quarter and full-year 2022 financial results on March 8, 2023, after the market close. A conference call will follow at 4:30 PM ET to discuss the results. Biofrontera specializes in dermatological products, particularly photodynamic therapy and topical antibiotics for conditions like actinic keratoses and impetigo. Investors can access the conference call using a toll-free number or through a webcast provided in the press release.
Biofrontera, Inc. (NASDAQ:BFRI) has been invited to present at the Third Annual Winter Wonderland - Best Ideas Virtual Investor Conference from February 21 to 24, 2023. CEO Erica Monaco and CFO Fred Leffler will represent the company, with the presentation scheduled for February 21 at 10:00 AM ET. Attendees can engage in one-on-one meetings with management during the conference. The presentation will be available for live streaming and replay. For further details, investors can reach out via email or register online.
Biofrontera specializes in dermatological products, particularly focusing on photodynamic therapy and topical antibiotics.
Biofrontera Inc. (Nasdaq:BFRI) has announced the initiation of a Phase 3 clinical trial to evaluate the safety and efficacy of Ameluz® and BF-RhodoLED® XL for treating actinic keratosis (AK) on the extremities, neck, and trunk. This study, involving 11 U.S. sites and about 165 patients, aims to meet the growing demand for effective AK therapies, impacting approximately 58 million Americans. Previous trials indicated 91% total clearance of AK on the face and scalp, showcasing Ameluz-PDT's potential to expand its market reach.